MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Arrowhead Pharmaceuticals Inc

Fermé

SecteurSoins de santé

12.72 4.78

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.93

Max

12.82

Chiffres clés

By Trading Economics

Revenu

-1.9M

-175M

Ventes

2.5M

2.5M

BPA

-1.39

Marge bénéficiaire

-7,008.72

Employés

609

EBITDA

4.9M

-148M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+232.79% upside

Dividendes

By Dow Jones

Prochains Résultats

8 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.9B

Ouverture précédente

7.94

Clôture précédente

12.72

Sentiment de l'Actualité

By Acuity

29%

71%

87 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Arrowhead Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 sept. 2024, 10:38 UTC

Principaux Mouvements du Marché

Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran

Comparaison

Variation de prix

Arrowhead Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

232.79% hausse

Prévisions sur 12 Mois

Moyen 40.6 USD  232.79%

Haut 80 USD

Bas 21 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

7

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 11.675Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

87 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.